Evidence map›Paper›PMID 25922680›Full record

ArticleUnited European gastroenterology journal2015

Prevalence estimation of celiac disease in the general adult population of Latvia using serology and HLA genotyping.

Marcis Leja, Zakera Shums, Liene Nikitina-Zake, Mikus Gavars, Ilze Kikuste, Jay Milo, Ilva Daugule, Jelena Pahomova, Valdis Pirags, Vilnis Dzerve and 3 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in United European gastroenterology journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Message from the editors: coeliac disease focused issue.United European gastroenterology journal · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Marcis LejaUniversity of Latvia, Faculty of Medicine, Riga East University Hospital, Riga, Latvia.
Zakera ShumsInova Diagnostics Inc, San Diego, CA, USA.
Liene Nikitina-ZakeLatvian Biomedical Research and Study Centre, Riga, Latvia.
Mikus GavarsUniversity of Latvia, Riga, Latvia.
Ilze KikusteUniversity of Latvia, Riga, Latvia.
Jay MiloInova Diagnostics Inc, San Diego, CA, USA.
Ilva DauguleUniversity of Latvia, Riga, Latvia.
Jelena PahomovaInstitute of Cardiology, University of Latvia, Riga, Latvia.
Valdis PiragsUniversity of Latvia, Faculty of Medicine, Pauls Stradins Clinical University Hospital, Riga, Latvia.
Vilnis DzerveInstitute of Cardiology, University of Latvia, Riga, Latvia.
Janis KlovinsLatvian Biomedical Research and Study Centre, Riga, Latvia.
Andrejs ErglisInstitute of Cardiology, University of Latvia, Riga, Latvia.
Gary L NormanInova Diagnostics Inc, San Diego, CA, USA.
University of Latvia · LVNova Medical (United States) · USLatvian Biomedical Research and Study Centre · LVPauls Stradiņš Clinical University Hospital · LVRiga East University Hospital · LV

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrevalence estimates for celiac disease (CD) depend on the method used. The role of deamidated gliadin peptide (DGP) and genetic testing in epidemiological studies and diagnostic settings of celiac disease (CD) has still to be established.

objectivesThe objective of this article is to assess the prevalence of CD in Latvia by combining serological tests with DQ2.5/DQ8 testing.

methodsA total of 1444 adults from a randomly selected cross-sectional general population sample were tested by ELISA for tTG IgA, DGP IgA and IgG antibodies (QUANTA Lite®, Inova Diagnostics Inc). Samples with tTG IgA ≥20U were tested for EMA IgA by indirect immunofluorescence assay, and all specimens with tTG IgA ≥15U were tested by QUANTA-Flash® chemiluminescent assays (CIA) (Inova Diagnostics Inc) for tTG IgA, DGP IgA and IgG. DQ2.5/8 was detected in individuals with any positive ELISA test and a subgroup of controls.

resultsForty-three individuals (2.98%; 95% CI: 2.10-3.86%) tested positive by at least one ELISA test; 41.86% of the serology-positive individuals (any test above the cutoff) were DQ positive. Six individuals (0.42%; 95% CI: 0.09-0.75%) were triple ELISA positive, and DQ2.5 or DQ8 was positive in all; 0.35% (95% CI: 0.05-0.65%) were tTG IgA and EMA positive. Two tTG IgA-negative cases were both DGP IgG and IgA positive, both being DQ positive; including them in the "serology-positive" group would increase the prevalence to 0.49% (95% CI: 0.13-0.85%). CIA tests revealed 2 tTG IgA-positive and EMA-negative cases with a positive genotype. DQ2.5 or DQ8 genotype was positive in 28.6% of the serology-negative population.

conclusionsEstimates of the prevalence of CD in Latvia based on the serogenetic testing approach range from 0.35% to 0.49% depending on the criteria used. There is a rationale for combining serological tests and DQ2.5/8 genotyping.

Indexed as

Celiac diseasechemiluminescent assaysdeamidated gliadin peptideDQ2.5/8 genotypeEastern Europeprevalencetissue transglutaminase

Identifiers

PMID25922680
PMCPMC4406903
OpenAlexW2161976053

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.